Weekly Investment Analysts’ Ratings Updates for Bristol Myers Squibb (BMY)

Several analysts have recently updated their ratings and price targets for Bristol Myers Squibb (NYSE: BMY):

• 2/24/2026 – Bristol Myers Squibb is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $60.00 price target on the stock.
• 2/24/2026 – Bristol Myers Squibb is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $60.00 price target on the stock.
• 2/23/2026 – Bristol Myers Squibb had its “overweight” rating reaffirmed by Piper Sandler. They now have a $75.00 price target on the stock, up from $66.00.
• 2/19/2026 – Bristol Myers Squibb is now covered by Barclays PLC. They set an “overweight” rating and a $75.00 price target on the stock.
• 2/19/2026 – Bristol Myers Squibb is now covered by Barclays PLC. They set an “overweight” rating and a $75.00 price target on the stock.
• 2/6/2026 – Bristol Myers Squibb had its “underweight” rating reaffirmed by Morgan Stanley. They now have a $40.00 price target on the stock.
• 2/6/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Guggenheim. They now have a $72.00 price target on the stock, up from $62.00.
• 2/6/2026 – Bristol Myers Squibb had its “outperform” rating reaffirmed by Wells Fargo & Company. They now have a $60.00 price target on the stock, up from $55.00.
• 2/6/2026 – Bristol Myers Squibb had its price target raised by Citigroup Inc. from $60.00 to $64.00. They now have a “neutral” rating on the stock.
• 1/28/2026 – Bristol Myers Squibb had its “overweight” rating reaffirmed by Piper Sandler. They now have a $66.00 price target on the stock, up from $62.00.
• 1/27/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $60.00 price target on the stock, up from $53.00.
• 1/13/2026 – Bristol Myers Squibb had its price target raised by Leerink Partners from $54.00 to $60.00. They now have an “outperform” rating on the stock.
• 1/9/2026 – Bristol Myers Squibb had its “sector perform” rating reaffirmed by Scotiabank. They now have a $60.00 price target on the stock, up from $53.00.
• 1/7/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $53.00 price target on the stock, up from $45.00.
• 1/7/2026 – Bristol Myers Squibb was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $65.00 price target on the stock, up from $46.00.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 73.04%.

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.